Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Bo Didley who wrote (2848)	10/25/2000 3:38:26 PM
From: StockDung	Read Replies (1) \| Respond to of 5582

A BEVY of good news for GUMM yet the stock continues to SINK!! To: Doug R who started this subject From: Bo Didley Thursday, Sep 14, 2000 7:54 PM ET Reply # of 37370 * * GUMM * * Chart ready for breakout stockcharts.com[L,A]DAOL... Notice the accumulation, money flow, upward trend breaking out of an ascending triangle. Info: GUMM owns Zicam. Remedy for the common cold. Played here last January and ran it to $36. Guess what, its back in play, buy now and you'll be early, imo. zicam.com -- What's coming up is research clinicals in a journal that shows Zicam effective reducing a 14 day common cold to last only 3 days. That is revolutionary! We know 1. Dr. Hirt conducted research using Zicam at onset. One study yielded 78% another one 72% effective, respectfully. The news release said he would submit these to a journal. He has two studies he could submit separately, or combine them into one. I would expect a journal to publish these to correspond with the seasonality of the common cold. When this is released, expect a strong move in the price. Human interest momentum from possible talk on TV News and other media. (They hired Kovel Fuller to do the PR kovelfuller.com 2. We know independant research on Zicam has been on going for the Preventative claims. In a news released dated July 1999, GUMM announced they would be seeking data for Zicam PREVENTING the common cold. Some believe Dr. Turner, the most respected, world known rhinovirus virologist has been conducting the studies. He did the research for VPHM, which research moved it from $11's to $111. He's had plenty of time to complete the research for ZICAM. Same reasoning, I would expect news of Preventative status to occur sometime during the seasonality of the common cold. American populous is very big on prevention of illness. So is the medical community. If the studies show significant statistics and Dr. Turner is the head Investigator, this will be huge huge news. Zicam is already in over 50,000 stores and Preventative Claims would promote it well in hospitals and clinics, a life saving medicine among the immunosuppressed patients. But it needs credible research first showing significant statistics by a well known researcher. The Chart and the above two reasons is why I am back in GUMM to correspond with the seasonality of news and journals. This is a short term, seasonal investment. Other information at gumminvestors.com If you like this as an investment, let your friends know about it. bo

To: Bo Didley who wrote (2848)	10/25/2000 4:13:17 PM
From: Mad2	Respond to of 5582

brilliantNothing counts until you actually cover. Can I infer that the same applies to a long position?.....i.e. its meaningless until you sell? If so how are you making out on this position? Message 12804908 To: Street Walker who wrote (2215) From: Bo Didley Tuesday, Feb 8, 2000 12:26 AM ET Reply # of 2848 Holding my GUMM, awaiting Q1 earnings blast off ! GUMM price ready to move up on Tuesday, technical buying area. messages.yahoo.com. $20M in sales estimated for Q1, up from $8M sales Q4 will send this stock soaring. Then International distribution just in time for all the 50,000 US stores stalking their warehouses for next fall. Then we start the inception of the Nicotine GUMM being sent to 140 countries after test marketing. I can't believe how undervalued this stock is. It needs a brokerage firm to even know that it exists so coverage can be initiated. It is an easy Tripple in the next 11 months. What price do you think they'll do a stock split? $50 or $60 ? bo Bo, with a handle like Didley, I'm surprised to find that you don't know Didley You should leave the stock picking and projection business to the professionals, at least until your track record justifies listening to what you have to say. m2